drugset / Trial / NCT00838383

Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery

NCT00838383

Phase 2 Completed 29 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-center, randomized study of sitaxsentan administered intravenously to subjects who are undergoing elective CABG, cardiac valve replacement, or combined CABG and cardiac valve replacement procedures that require CPB.

Timeline

Start
2006-08-10
Primary completion
2008-03-31
Completion
2008-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitaxentan Small molecule 1 mg/kg Intravenous
Subject Sitaxentan Small molecule 2 mg/kg Intravenous

Indications

No indication recorded.